ZIA CP010226-10771 (ZIA) | |||
---|---|---|---|
Title | Next Gen Cohort - Core Activities | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Hoover, Robert | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $3,267 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Cancer Survivorship (10.0%) Diabetes (10.0%) Sleep Disorders (10.0%) Smoking Behavior (10.0%) |
N/A | ||
Research Type | |||
Resources and Infrastructure Related to Etiology Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis |
|||
Abstract | |||
"Due to the changing nature of most exposures related to cancer, a prospective cohort study design is central to the study of cancer etiology and prevention. Recent developments in the assessment of external exposures and biomarkers to measure internal exposures, as well as detailed imaging and molecular characterization of tissues, provide unprecedented opportunities to understand the causes of different types of cancer. This knowledge is critical to inform preventive strategies. A new biospecimen-based prospective cohort in the USA to capture contemporary exposures changing over time through repeated assessments during follow up, will be an extremely valuable resource for cancer research. Feasibility studies have confirmed the value of conducting a new cohort in a set of integrated healthcare systems (IHCS), with electronic medical records (EMRs), a passive follow-up system that is both cost-effective and thorough, and existing clinical infrastructure for biospecimen collection. The proposed study population will include adults from a diverse group of IHCS across the U.S. Consented participants will complete an E-questionnaire at baseline and periodically throughout the duration of follow-up. Passive follow-up via tumor registries and EMRs will provide outcome information for diagnoses of new cancers and its precursors. Blood, urine and mouthwash samples will be collected at baseline and repeatedly during follow up in the local clinics. Normal, precursor and tumor tissue, fecal samples and other specimens will also be collected during follow up. The healthcare and online study setting will be dynamic and highly interactive, facilitating additional exposure assessments and biospecimen collections in the full cohort or subpopulations of interest. " |